Fostimon 150 I.U Vials

Fostimon 150 I.U Vials

Description:

Fostimon 150 i.u vials is a prescription fertility medicine containing purified urofollitropin, a human follicle stimulating hormone (FSH). It is used under specialist supervision to stimulate ovarian follicular growth in women with infertility who do not have primary ovarian failure. Fostimon is supplied as a powder for solution for intramuscular (i.m.) or subcutaneous (s.c.) injection and is typically used as part of controlled ovarian stimulation or ovulation induction protocols in assisted reproduction and infertility treatment programs.

Indications:

• Treatment of female infertility due to anovulation or oligo-ovulation (including polycystic ovary syndrome) in women without primary ovarian failure.
• Controlled ovarian stimulation to induce the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), intracytoplasmic sperm injection (ICSI), or other ART procedures.
• Stimulation of follicular development in women with inadequate response to clomiphene citrate or other first-line ovulation induction therapies, as directed by a fertility specialist.
• Management of hormonal infertility where exogenous FSH is required to promote follicular recruitment and maturation.

Active Ingredients / Key Components:

• Urofollitropin (Follicle Stimulating Hormone, FSH) – 150 international units (i.u) per vial (powder for solution for injection).
• Excipients: Specific excipients, stabilizers, and preservatives are not provided in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.). Please refer to the official package leaflet for the full list of inactive ingredients.

Dosage & Administration / How to Use:

• Fostimon 150 i.u must only be used under the supervision of a physician experienced in the treatment of infertility and in a setting with appropriate monitoring facilities.
• Route of administration: Intramuscular (i.m.) or subcutaneous (s.c.) injection, as instructed by the treating physician.
• Reconstitution: The powder in the vial should be reconstituted with the provided solvent (usually sterile diluent) according to the manufacturer’s instructions. Gently swirl (do not shake vigorously) until the powder is completely dissolved and the solution is clear.
• Typical dosing in anovulatory patients (including PCOS): The starting dose and subsequent adjustments are individualized. The dose is usually given once daily for several days. The physician will adjust the dose based on ovarian response assessed by ultrasound and/or serum estradiol levels. Exact dosing schedules vary and must follow the specialist’s protocol.
• Typical dosing in ART (e.g., IVF): Fostimon is administered daily from day 2 or 3 of the menstrual cycle to stimulate multiple follicle development. Dose and duration depend on the patient’s response and treatment protocol.
• When adequate follicular development is achieved, an injection of human chorionic gonadotropin (hCG) may be given to trigger ovulation, as directed by the fertility specialist.
• Do not self-adjust the dose or duration. Never use more or less than prescribed. If a dose is missed, contact your doctor immediately for instructions.
• Use immediately after reconstitution. Discard any unused solution safely according to pharmacist or clinic instructions.

Clinical Benefits:

• Stimulates ovarian follicular growth in women with infertility by providing exogenous follicle stimulating hormone (FSH).
• Promotes recruitment and development of multiple ovarian follicles, which is essential for assisted reproductive technologies such as IVF and ICSI.
• Helps induce ovulation in women who do not ovulate regularly or who are resistant to first-line ovulation induction therapies.
• Supports individualized, controlled ovarian stimulation protocols, allowing fertility specialists to tailor treatment based on ovarian response and improve chances of successful conception.

Warnings & Contraindications:

• Fostimon 150 i.u is a potent fertility medicine and must only be used under strict medical supervision with appropriate monitoring (ultrasound and hormone tests).
• Contraindicated in women with primary ovarian failure, ovarian enlargement or cysts not due to polycystic ovary syndrome, unexplained vaginal bleeding, hormone-dependent tumors of the reproductive organs or breast, or tumors of the hypothalamus or pituitary gland.
• Contraindicated in pregnancy and during breastfeeding. Treatment should be discontinued if pregnancy occurs.
• Use with extreme caution in women at risk of ovarian hyperstimulation syndrome (OHSS), such as those with polycystic ovary syndrome. Dose adjustments and close monitoring are essential.
• There is an increased risk of multiple pregnancy (twins or more) and ectopic pregnancy with fertility treatments. Discuss these risks with your doctor before starting therapy.
• Thromboembolic events (blood clots) have been reported in association with gonadotropin therapy, especially in women with known risk factors. Inform your doctor if you have a history of thrombosis, clotting disorders, obesity, or prolonged immobilization.
• Consult your doctor before use if you have liver disease, kidney disease, uncontrolled thyroid or adrenal disorders, or other serious medical conditions.
• Not intended to diagnose, treat, cure, or prevent any disease without proper medical supervision. This medicine is strictly prescription-only.
• Keep out of reach of children. Do not share this medication with anyone.
• Always inform your doctor about all medicines, supplements, or herbal products you are taking to avoid interactions.

Side Effects:

• Common side effects may include injection site reactions (pain, redness, bruising), headache, abdominal discomfort or bloating, nausea, breast tenderness, and mild pelvic pain.
• Ovarian hyperstimulation syndrome (OHSS) is a potentially serious side effect characterized by severe abdominal pain, rapid weight gain, nausea, vomiting, diarrhea, shortness of breath, and decreased urine output. Seek urgent medical attention if these symptoms occur.
• Other possible side effects include mood changes, fatigue, dizziness, and mild fluid retention.
• Serious but less common side effects may include thromboembolic events (blood clots), severe allergic reactions (rash, itching, swelling, difficulty breathing), or ovarian torsion. Immediate medical attention is required if any severe symptoms appear.
• This is not a complete list of side effects. Always consult your doctor or pharmacist if you experience any unusual or persistent symptoms during treatment.

Storage Instructions:

Store in a cool, dry place away from direct sunlight, heat, and moisture. Keep vials in their original packaging until use to protect from light. Do not use after the expiry date printed on the pack. After reconstitution, use the solution immediately as directed and discard any remaining solution safely. Keep out of reach of children.

Specifications:

• Form: Powder for solution for injection (i.m./s.c.).
• Strength: 150 i.u urofollitropin per vial.
• Intended use: Prescription fertility medicine for controlled ovarian stimulation and ovulation induction in women.
• Pack size: Number of vials per pack is not specified in the available information (For full ingredient information, please check the product leaflet or the manufacturer’s official website.); please refer to the product packaging.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.